Galapagos announces completion of patient enrollment for DIVERSITY Phase 3 study with filgotinib in Crohn’s Disease

NEXT STORY
DeepUll Appoints Richard Ivey to its Board of Directors
PREV STORY
Active Biotech: Tasquinimod clinical  development in multiple myeloma advances into combination therapy following completion of the initial phase of the ongoing trial in the US
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Checkpoint Therapeutics Announces Confirmation of Registration Path for Cosibelimab in Metastatic Cutaneous Squamous Cell Carcinoma

author_avatar
NASDAQ Market News

Konica Minolta’s Exa Platform Helps Green Bay Radiology Grow While Streamlining Operations

WAYNE, N.J., March 20, 2018 (GLOBE NEWSWIRE) -- Konica Minolta Healthcare Americas, Inc. announces ...

author_avatar
NASDAQ Market News

DBGS and Regenerative Materials (Dental Devices) – Global Market Analysis and Forecast Model (COVID-19 Market Impact)

author_avatar
NASDAQ Market News